MR-proADM

Mid-Regional Pro-Adrenomedullin (MR-proADM): A Superior Prognostic Sentinel in Transthyretin Cardiac Amyloidosis

This review synthesizes recent evidence identifying MR-proADM as a premier prognostic biomarker in ATTR-CM, demonstrating its ability to outperform traditional natriuretic peptides and enhance existing clinical staging systems.